Resources Investment Advisors, Llc. Fate Therapeutics Inc Transaction History

Resources Investment Advisors, Llc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 23, 2022	SELL	$47.84 - $64.34 $1,435 - $1,930	-30 Reduced 0.87%	3,419 $200,000
Q3 2021 Nov 05, 2021	BUY	$59.27 - $95.73 $3,615 - $5,839	61 Added 1.8%	3,449 $204,000
Q2 2021 Aug 09, 2021	SELL	$67.25 - $92.52 $1.94 Million - $2.67 Million	-28,896 Reduced 89.51%	3,388 $294,000
Q1 2021 May 10, 2021	SELL	$72.16 - $117.4 $238,344 - $387,772	-3,303 Reduced 9.28%	32,284 $2.66 Million
Q4 2020 Feb 08, 2021	SELL	$38.09 - $100.95 $243,852 - $646,281	-6,402 Reduced 15.25%	35,587 $3.24 Million
Q3 2020 Oct 09, 2020	SELL	$30.41 - $40.5 $449,307 - $598,387	-14,775 Reduced 26.03%	41,989 $1.68 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $110,609 - $192,813	5,473 Added 10.67%	56,764 $1.95 Million
Q1 2020 May 14, 2020	SELL	$17.28 - $31.88 $95,990 - $177,093	-5,555 Reduced 9.77%	51,291 $1.14 Million
Q4 2019 Feb 07, 2020	BUY	$13.39 - $20.73 $365,506 - $565,866	27,297 Added 92.38%	56,846 $1.11 Million
Q3 2019 Nov 08, 2019	SELL	$15.47 - $22.5 $34,498 - $50,175	-2,230 Reduced 7.02%	29,549 $458,000
Q2 2019 Aug 12, 2019	BUY	$15.61 - $20.44 $496,070 - $649,562	31,779 New	31,779 $0

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Resources Investment Advisors, Llc., based on Form 13F filings with the SEC.

Stay updated on Resources Investment Advisors, Llc. with notifications on news.